These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3547612)

  • 1. Protective drugs in the treatment of gastroduodenal ulcer disease.
    Koelz HR
    Scand J Gastroenterol Suppl; 1986; 125():156-64. PubMed ID: 3547612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ulcer therapy without acid inhibition].
    Koelz HR
    Schweiz Med Wochenschr; 1984 May; 114(20):686-93. PubMed ID: 6547542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tripotassium-dicitrato-bismuthate (TDB) and cimetidine in peptic ulcer disease, a control study of 40 gastric ulcer and 80 duodenal ulcer.
    Chearanai O; Kachintorn U; Plengvanit U
    J Med Assoc Thai; 1987 Apr; 70(4):176-80. PubMed ID: 3612003
    [No Abstract]   [Full Text] [Related]  

  • 4. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer.
    Bianchi Porro G; Lazzaroni M; Manzionna G; Petrillo M
    Aliment Pharmacol Ther; 1998 Apr; 12(4):355-60. PubMed ID: 9690725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer.
    Hamilton I; Worsley BW; O'Connor HJ; Axon AT
    Gut; 1983 Dec; 24(12):1148-51. PubMed ID: 6357964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN; Nio CY
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptic ulcer therapy with cimetidine versus tripotassium dicitrato bismuthate in rheumatoid arthritis patients undergoing chronic NSAID treatment.
    Bianchi Porro G; Lazzaroni M; Petrillo M; Ardizzone S; Manzionna G; Caruso I; Montrone F
    Aliment Pharmacol Ther; 1998 Apr; 12(4):343-7. PubMed ID: 9690723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer.
    Banerjee S; El-Omar E; Mowat A; Ardill JE; Park RH; Watson W; Beattie AD; McColl KE
    Gastroenterology; 1996 Mar; 110(3):717-24. PubMed ID: 8608880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why do ulcers heal with sucralfate?
    Lam SK
    Scand J Gastroenterol Suppl; 1990; 173():6-16. PubMed ID: 2190306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correlation between acid suppression and peptic ulcer healing.
    Hunt RH; Howden CW; Jones DB; Burget DW; Kerr GD
    Scand J Gastroenterol Suppl; 1986; 125():22-31. PubMed ID: 3469740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sucralfate and cimetidine in the treatment of duodenal and gastric ulcers. A multicenter study.
    Pop P; Nikkels RE; Thys O; Dorrestein GC
    Scand J Gastroenterol Suppl; 1983; 83():43-7. PubMed ID: 6356320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sucralfate: the Bangkok review.
    Korman MG; Bolin TD; Szabo S; Hunt RH; Marks IN; Glise H
    J Gastroenterol Hepatol; 1994; 9(4):412-5. PubMed ID: 7948825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. There is more to healing ulcers than suppressing acid.
    Colin-Jones DG
    Gut; 1986 May; 27(5):475-80. PubMed ID: 3084343
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of cytoprotective agents in the treatment of gastric ulcers.
    Lam SK
    Med J Aust; 1985 Feb; 142 Spec No():S21-3. PubMed ID: 3841578
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of protective drugs in the prevention of ulcer relapse.
    Ota S; Terano A
    J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriate acid suppression in the treatment of acid-related conditions.
    Howden CW
    Pharmacol Ther; 1994; 63(1):123-34. PubMed ID: 7972343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoprotective agents and ulcer relapse.
    McLean AJ; McCarthy P; Dudley FJ
    Med J Aust; 1985 Feb; 142(3):S25-8. PubMed ID: 3838199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of mucosal protection.
    Blum AL; Koelz HR; Inauen W
    Scand J Gastroenterol Suppl; 1986; 125():189-94. PubMed ID: 3469738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Spencer R; Avery GS
    Drugs; 1976; 11(4):245-307. PubMed ID: 780088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cytoprotective agents in the treatment of gastric ulcers.
    Lam SK
    Med J Aust; 1985 Feb; 142(3):S21-3. PubMed ID: 3881652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.